Search

Displaying results 3631 - 3640 of 5263 in total
  1. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexo...

  2. Drug

    Aminophylline

    go.drugbank.com/drugs/DB01223
    ApprovedInvestigational

    Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase ...

    Products: DRAFILYN Z
  3. Drug

    Perflubutane

    go.drugbank.com/drugs/DB12821
    ApprovedInvestigationalWithdrawn

    Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable ultrasound to compete more e...

  4. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells. … The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions.

  5. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug desig...

  6. Drug

    NE-180

    go.drugbank.com/drugs/DB05619
    Experimental

    NE-180 was under investigation in a clinical trial conducted in the European Union.

  7. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells.

  8. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by

  9. Drug

    Celastrol

    go.drugbank.com/drugs/DB18736
    Experimental

    Celastrol is a pentacyclic triterpenoid isolated from the root extracts of _Tripterygium wilfordii_.[L50567]

  10. Drug

    DiaPep 277

    go.drugbank.com/drugs/DB06651
    Investigational

    DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).